Clinical trial results: *PROSPECTIVE EVALUATION OF SERUM MALDI TOF MS PROTEOMIC PROFILE PREDICTIVE OF OUTCOME IN PATIENTS WITH GLIOBLASTOMA MULTIFORME TREATED WITH STANDARD TREATMENT STRATIFIED ACCORDING TO MGMT METHYLATION STATUS*

Summary

EudraCT number*	2009-013662-33
Trial protocol	GICNO08-001
Global end of trial date*	31Dec2012

Trial information

Trial identification	
Sponsor protocol code*	GICNO08-001

Additional study identifiers	
ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors details*	
Sponsor organisation name	IRCCS Ospedale San Raffaele
Sponsor organisation address	Via Olgettina, 60, Milano, Italy, 20132
Public contact	reni.michele@hsr.it
Scientific contact	reni.michele@hsr.it

Notes:

Paediatric regulatory details*	
Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Results analysis stage	
Analysis stage*	Final
Date of interim/final analysis*	Dec 2012
Is this the analysis of the primary completion data?*	Yes
Global end of trial reached?*	Yes
Global end of trial date*	31Dec2012
Was the trial ended prematurely?	YES

General information about the trial

Main objective of the trial*: to identify a serum proteomic profile in patients with newly diagnosed glioblastoma multiforme treated with standard therapy

Actual start date of recruitment*	17/06/2009
Long term follow-up planned*	NO
If Yes, rationale:	Safety Efficacy Ethical reason Regulatory reason Scientific research
Duration	-
Independent data monitoring committee (IDMC) involvement?*	No
Protection of trial subjects*:	
Background therapy:	No
Evidence for comparator:	

Population of trial subjects

Subjects enrolled per country

Country:	Italy
Planned number of subjects	30
Actual Number of subjects enrolled*	21
Worldwide total number of subjects	0
EEA total number of subjects	21 (only in Italy)

Subjects enrolled per age group

In utero*	N/A
Preterm newborn - gestational age < 37wks*	N/A
Newborns (0-27 days)*	N/A
Infants and toddlers (28 days-23months)*	N/A
Children (2-11 years)*	N/A
Adolescents (12-17 years)*	N/A
Adults (18-64 years)*	18
From 65 to 84 years*	3
85 years and over*	0

Subject disposition

Recruitment details:

Enrollment from 11Feb2009 to 01Aug2011 in 1 clinical center

Pre-assignment - *Screening details*:

The study population consists of adult Caucasian patients (≥ 18 years old) affected by glioblastoma multiforme

Inclusion criteria

- Written informed consent obtained before undergoing any study-related activities
- Age ≥18 and <70 years
- Newly diagnosed histologically proven supratentorial GBM (World Health Organization [WHO] Grade IV). The histological diagnosis must be obtained from a neurosurgical resection of the tumor or by an open biopsy
- Tumor tissue specimens from the GBM surgery or open biopsy (formalin-fixed, paraffin-embedded block) must be available for MGMT status analysis and central pathology review
- Disease evaluated by contrast enhanced (Gd) MRI within 2 weeks prior to the start of the treatment
- ECOG/WHO PS of 0-1
- RPA-EORTC class III-IV (Appendix A) [13]
- Patient candidated to standard treatment according to EORTC 26981-22981 study (i.e. TMZ given at the dose of 75 mg/m² on a daily basis concomitantly to RT and for a maximum of 7 weeks. After 4 weeks rest at the end of RT, adjuvant TMZ is given at the dose of 150-200mg/m² every 4 weeks

Exclusion criteria

- Patient who can not comply with planned protocols procedures
- Prior chemotherapy within the last 5 years
- Prior RT of the head
- Receiving concurrent investigational agents or has received an investigational agent
- Prior anti-angiogenic therapy
- Placement of Gliadel® wafer at surgery
- Planned surgery for other diseases
- History of malignancy. Subjects with curatively treated cervical carcinoma in situ or basal cell carcinoma of the skin, or subjects who have been free of other malignancies for more than 5 years are eligible for this study
- Any uncontrolled intercurrent illness (e.g. high blood pressure, unstable angina, serious cardiac arrhythmia, diabetes …), also including severe infection, which may jeopardize the ability of the subject to receive the procedures outlined in this protocol with reasonable safety
- Subject is pregnant (positive pregnancy test [serum -HCG] at screening), or is currently breast-feeding
- Any psychological, familiar, sociological, legal or geographical state that could potentially interfere with the study protocol compliance; these conditions should be evaluated before patient's enrolment

Period 1

Period title*	*Overall Trial*
Is this the baseline period?	No

Allocation method*	Not applicable
Blinding used*	

Arms

Arm title*	**PROTEOMIC PROFILE**
Arm description:	serum proteomic profile in patients with newly diagnosed glioblastoma multiforme treated with standard therapy
Arm type*	Not applicable
Investigational medicinal product name*	Not applicable
Investigational medicinal product code	
Other name	
Pharmaceutical forms*	
Routes of administration*	
Dosage and administration details*	

Number of subjects in period	**PROTEOMIC PROFILE**	
Started*	21	
Completed*	2	
Subject non-completion reason (if applicable)		
AE, non fatal	0	
AE, fatal	0	
Consent withdrawn by subject	0	
Lack of efficacy	19	
Lost to follow up	0	
Physician decision	0	
Pregnancy	0	
Protocol Deviation		
Other		

Baseline characteristics

Reporting groups* Overall cohort	
Reporting group title*	**PROTEOMIC PROFILE**
Number of subjects at the baseline*	21 patients

Reporting group description: *You can report per arm in the baseline period or for the overall baseline period*

Subject analysis sets

Add a subject analysis set if you wish to report on groups different from the reporting group defined above (repeat if applicable)

Subject analysis set title*	
Subject analysis set type*	
Subject analysis set description*	
Number of subjects in subjects analysis set*	

Age characteristics*

Complete either the age categorical, age continuous or complete both these characteristics in order to collect values for the reporting groups and optionally the subject analysis sets.

	Characteristic title*	Units*	Age categories*
Age categorical			

	Characteristic title*	Units*	Central tendency*	Dispersion type*
Age continuous	Overall cohort	Years	Median 61 years	full range (min-max) 24-69 years

Gender characteristics*

	Characteristic title*	Units*	Gender categories*
Gender categorical	Gender	Count	Female: 16 Male: 5

Study specific characteristics

	Characteristic title*	Units *	Categories*	Number of subject for each categories
Study specific categorical				
Study specific categorical				
Study specific categorical				
Study specific categorical				
Study specific categorical				

End points

Add subject analysis set if you wish to report on groups different form reporting groups defined above

Subject analysis set title*	ALL PATIENTS
Subject analysis set type*	Per protocol
Subject analysis set description*	Correlation between proteomic profile and outcome, in terms of PFS and OS of patients with GBM treated with standard therapy
Number of subject in subject analysis set *	

End points definitions

End point title*	**Correlation between proteomic profile and Progression free Survival (PFS)**	
		Values
Countable or measurable?*	Measurable	Median PFS
If countable, Countable units*:		
If measurable, Measurable units*	Months	
Measure type*:	Median	
Precision/dyspersion type*	95% Confidence Interval (CI)	

End point type*	Primary

End point timeframe*: From start of therapy to PD

End point title*	**Correlation between proteomic profile and Overall survival (OS)**	
		Values
Countable or measurable?*	Measurable	Median overall survival
If countable, Countable units*:		
If measurable, Measurable units*	Months	
Measure type*:	Median	
Precision/dyspersion type*	95% Confidence Interval (CI)	

End point type*	Primary

End point timeframe*: From start of therapy to death from any cause

Use categories only if the data for the end point can be categorized

Category title

Specify the groups of subjects applicable to this end point

Reporting groups*			
Period			
Arms			
subject analysis sets			

Adverse events

Adverse events information

Timeframe for reporting adverse events*: *Enter the time point(s) or time period for AE assessment*
Only SAE, from start of treatment until 28 days after the last dose

Adverse event reporting additional description	
Assessment type*	Non Systematic
Frequency threshold for reporting non-serious adverse events*	

Dictionary used

Dictionary name*	CTCAE
Dictionary version*	3.0

Adverse events reporting group definition

Use arms from baseline period as reporting groups
OR

Reporting group title*:

For this reporting group, provide the following totals:

Subject exposed*	
Subjects affected by non -SAE*	
Total number of deaths (all causes)*	
Total number of deaths resulting from adverse event*	

Serious adverse event details and values

System organ class*: N/A – NO SAE

Event term*: N/A – NO SAE

Values for serious adverse event per reporting group *

Reporting groups	Subjects affected number	Subjects exposed number	Occurrences all number	Occurrences causally related to treatment number	Fatalities number	Fatalities causally related to treatment number

Non - Serious adverse event details and values

System organ class*: N/A

Event term*: N/A

Values for non-serious adverse event per reporting group*

Threshold for non-serious adverse event reporting is:

Reporting groups	Subjects affected number	Subjects exposed number	Occurrences all number

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol*? No

Date	Amendment

Notes:

Interruptions (globally)

Were there any global interruptions to the trial*? YES

If Yes, Interruption date 01Aug2011

Interruption description The protocol was definitely interrupted due to lack of patients

Limitations and caveats

None reported

Online references

None